Press Release

NEW2024-02-21 Daewoong Pharmaceutical's AI System Processes 800 Million Compounds, Boosting Obesity and Cancer Research

NEW2024-02-05 Daewoong Pharmaceutical Announces 2023 Financial Results

NEW2024-01-29 Daewoong Pharmaceutical's Bersiporocin Receives ‘Orphan Drug Designation’ in Europe to Treat Idiopathic Pulmonary Fibrosis

Daewoong Pharmaceutical's AI System Processes 800 Million Compounds, Boosting Obesity and Cancer Research 2024-02-21
Daewoong Pharmaceutical Announces 2023 Financial Results 2024-02-05
Daewoong Pharmaceutical's Bersiporocin Receives ‘Orphan Drug Designation’ in Europe to Treat Idiopathic Pulmonary Fibrosis 2024-01-29
Daewoong Pharmaceutical and Zydus Announce Exclusive Licensing Agreement for Development and Commercialization of Leuprolide Long-Acting Injectable in the U.S. 2023-12-11
Daewoong Pharmaceutical Strikes a $60 Million Deal with JSC Pharmasyntez for Diabetes Novel Drug Enavogliflozin 2023-12-06
Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA 2023-11-28
Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative 'GLP-1 Obesity Treatment' with Advanced Microneedle Technology for Sustained Weekly Efficacy 2023-11-07
Daewoong Pharmaceutical Reports Third Quarter 2023 Financial Results 2023-11-06
Daewoong Pharmaceutical announces ‘3E Global Hyper-Competitive Strategy' at CPHI 2023... Aiming for USD 745M in novel drug sales by 2030 2023-10-26

이전 페이지 1 / 44다음 페이지

Search